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Despite the significant progress made in pre-
venting and treating cardiovascular disease (CVD)
is still the leading cause of death in the developed
world, and death due to CVD is still increasing in
these nations. Approximately 130 million people in
the seven major pharmaceutical markets suffer from
CVD. Hypertension and atherosclerosis are central
to the pathogenesis of coronary artery disease
(ischemia, angina, myocardial infarction), heart fail-
ure, cerebral (stroke) and peripherial vascular dis-
ease (1-4).
There are several cardiac receptor systems that
are involved in regulation of contractility and/or
hearth rate. Among these, are receptors coupled to
the Gs-protein-adenylyl cyclase pathway (β-adreno-
ceptors (β-ARs), histamine-receptors, serotonin-
receptors), receptors coupled to the Gi-protein-
adenylyl cyclase pathway (muscarinic-receptors,
adenosine-receptors), and receptors that couple to
the Gq/ll-protein-phospholipase C-protein kinase C
pathway (α1-ARs, endothelin-receptors, angiotensin
II-receptors). A vast body of evidence has accumu-
lated that in heart failure, α1- and β-ARs changes
play an important role. α1-ARs modulate intercellu-
lar biochemical processes in response to changes in
extracellular concentration of the neurotransmitter,
norepinephrine, and circulating hormone, epineph-
rine (5-9). Compounds acting as antagonists at vari-
ous post-junctional α1-ARs are frequently used in
the therapy of high blood pressure, prazosin being
the most common drug (6). α1-ARs antagonists are
also used in the treatment of benign prostatic hyper-
plasia, lower urinary tract symptoms or cardiac
arrhythmia (8).
To date, a vast array of structurally unrelated
α1-ARs antagonists have been identified, which
makes it difficult to determine the structural require-
ments that lead to receptor selectivity (10-16).
However, some general rules have been postulated
by Barbaro et al. (17) and Bremner et al. (18). These
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are: an aromatic region, a basic nitrogen atom with
at least one available protonation site and a semipo-
lar region. 
This work is part of our rational drug design
project. We have previously reported that a series of
1-[3-(4-arylpiperazin-1-yl)-2-hydroxy]- or -propyl-
pyrrolidin-2-one derivatives possess affinity for α1-
and α2-ARs and show marked hypotensive and
antiarrhythmic activities. Among the compounds
tested, the most active were 1-[2-hydroxy-3-(4-
phenylpiperazin-1-yl)-propyl]-pyrrolidin-2-one (1)
and those which contain the propyl linker (2) (19-
22). Taking into consideration that the interactions
between ligand and receptor may depend on config-
uration of the asymmetric atom, the enantiomers of
compound (1) and its analogues were investigated.
It was found that their (S) enantiomers displayed
higher affinity for α1-ARs than (R) ones (23).
Additionally, in our last studies, quantitative rela-
tionship (QSAR) model explaining the α1-ARs
activity of a series of 1-[3-(4-arylpiperazin-1-yl)-
propyl]-pyrrolidin-2-one derivatives was reported
(24). This approach was based on the assumption
that the variation of the behavior of compounds, as
expressed by any measured biological activity,
could be correlated with structural features and a
physicochemical property (called descriptors) of a
set of chemicals compounds (25-30). The molecular
descriptors of the α1-ARs antagonists were obtained
by quantum chemical calculations combined with
molecular modeling calculations (31, 32). The
obtained model was correlated with coefficient
equal 0.9, explains more than 88% of the variance
and it was successfully validated by appropriate
tests such as LOO, LMO and external test. There
was also proven that the good statistics obtained for
proposed QSAR model is not due to chance correla-
tion or structural dependency of the training set (Y-
scrambling test). The 7-parametric equation defines
the best model for the data (24). The statistical
analysis showed that the α1-ARs activity of these
compounds are mainly determined by PCR,
HATS1m, E2m, RDF095p, Qindex, T(O..O), and
T(N..F) values (33). On the basis of these results and
previous evidence, we could conclude that the inter-
action of the arylpiperazinyl and arylpiperidinyl
moieties with the α1-adrenoreceptor depends on the
structure and geometry of the molecule rather than
on its physicochemical properties (24). 
According to this, the aim of these studies was
to synthesize new derivatives of arylpiperazine
propylpyrrolidin-2-one or arylpiperidine propyl-
pyrrolidin-2-one derivatives, then measure their bio-
logical activity and verified the QSAR model (24).
Firstly, the role of piperazine ring in template com-
pounds (1) and (2) was tested by replacement of this
moiety by a piperidine ring. Then, the 2-hydroxy-
propyl fragment of the obtained compound was
changed by a propyl one. The analogues of com-
pound (1) and its piperidine equivalent having 3-
alkyl-3-phenylpirrolidin-2-one fragment were syn-
thesized. These modifications in the pirrolidin-2-one
moiety included an introduction of phenyl- or alkyl-
(methyl-, ethyl-, n-propyl-, i-propyl-) groups. The
newly synthesized compounds were tested for α1-
ARs as well as for their antiarrhythmic and hypoten-
sive activity (Fig. 1).
EXPERIMENTAL
Chemistry
Melting points were determined in open glass
capillaries on the B¸chi 353 melting point apparatus
and are uncorrected. Elemental analyses (C, H, N)
were performed on an Elementar Vario EL III
(Elementar Analysensysteme, Hanau, Germany)
and were within ± 0.4% of the theoretical values.
The reaction performed using microwaves were car-
ried out in CEM Discover (CEM Corporation,
Matthews, USA) microwave reactor; 1H-NMR and
13C-NMR spectra were recorded on Varian Mercury
VX 300 MHz instrument in DMSO-d6 or CDCl3 at
ambient temperature using solvent signal as an
internal standard. Thin layer chromatography was
carried out on Merck silica gel pre-coated F254 plates
(0.2 mm) using chloroform/acetone (1:1, v/v), as a
developing system. The plates were visualized with
the UV light, iodine solution (0.05 M in 10% HCl)




A solution of 1.4 g (10 mmol) 2,3-epoxypropyl-
pyrrolidin-2-one (4) and 1.6 g (10 mmol) 4-
phenylpiperidine was heated in a closed vessel in
microvave reactor 300 W in 150OC for 30 min. The
progress of the reaction was monitored by TLC. The
obtained oily residue was purified by column chro-
matography using a mixture chloroform : acetone
(1:1, v/v). Then, the obtained oil was dissolved in
EtOH and then EtOH saturated with HClgas was
added until the mixture become acidic. The obtained
precipitate was crystallized from EtOH.
Yield 2.5 g (68%), m.p. 198-199OC, Rf (acetone :
CHCl3 1:1) 0.47. 1H-NMR (DMSO-d6, δ ppm): 1.77-
1.83 (m, 4H, CH2CH (piper.)), 1.99 (m, 2H,
CH2CH2CH2 (pyrrol.)), 2.32 (t, 2H, J = 7.1 Hz,
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CH2CO), 2.41-2.63 (m, 6H, CH(OH)CH2N, NCH2),
2.78 (qw., J = 7.0 Hz, 1H, CH), 3.29-3.43 (m, 4H,
CH2CH2N, NCH2CH(OH)), 3.58 (s, wide, 1H, OH),
4.08 (m, 1H, CHOH), 7.30-7.37 (m, 5H, arom.); 13C-
NMR (DMSO-d6, δ ppm): 17.7 (CH2CH2CO), 31.0
(CH2CO), 33.2, 42.0, 48.8 (piper.), 51.0 (CH2N
(pirol)), 54.4 (CH2), 63.8 (CH2), 66.5 (CHOH), 126.0,
128.1, 128.8, 146.5 (arom), 174.9 (carbonyl). Analysis:
calc. for C18H26N2O2 ◊ 2HCl, M = 375.33: C 57.60, H
7.52, N 7.46%; found: C 57.78, H 7.76, N 7.54%.
1-(3-(4-Phenylpiperidin-1-yl)propyl)pyrrolidin-2-
one dihydrochloride (7)
1.6 g (10 mmol) of 1-(3-chloropropyl)pyrro-
lidin-2-one (6) and 1.6 g (10 mmol) 4-phenylpiperi-
dine were heated in a closed vessel in microvave
reactor 300 W in 150OC for 40 min. The progress of
the reaction was monitored by TLC. The obtained
oily residue was purified by column chromatogra-
phy using a mixture of chloroform : acetone (1:1,
v/v) as a solvent. Then, the obtained oil was dis-
solved in EtOH and HCl gas was bubbled thought
the solution until the mixture become acidic. The
obtained precipitate was crystallized from EtOH. 
Yield: 2.6 g (73%), m.p. 215-216OC, Rf (ace-
tone : CHCl3 1:1, v/v) 0.53. 1H-NMR (DMSO-d6, δ
ppm): 1.70-1.83 (m, 6H, CH2CH (piper.),
CH2CH2CH2), 1.99 (m, 2H, CH2CH2CH2 (pyrrol.)),
2.31-2.47 (m, 8H, CH(OH)CH2N, NCH2, CH2CO),
2.78 (q, J = 7.0 Hz, 1H, CH), 3.29-3.43 (m, 4H,
CH2CH2N, NCH2CH(OH)), 7.30-7.37 (m, 5H,
arom.). 13C-NMR (DMSO-d6, δ ppm): 17.7
(CH2CH2CO), 26.2 (CH2CH2CH2), 31.0 (CH2CO),
33.2, 42.0, 48.5 (piper.), 48.6 (CH2CH2), 50.7
(CH2N), 52.2 (CH2), 126.0, 128.1, 128.8, 146.5
(arom.), 174.9 (carbonyl). Analysis: calc. for
C18H26N2O ◊ 2HCl, M = 359.33: C 60.16, H 7.85, N
7.80%; found: C 60.43, H 7.94, N 7.92%. 
(2R)-1-(3-Chloro-2-hydroxypropyl)-3-alkyl-3-
phenylpyrrolidin-2-one (9 a-e) ñ general procedure
To an ice-cold suspension of 60% NaH (2.6 g,
65 mmol) in 130 mL THF 3-alkyl-3-phenylpyrro-
lidin-2-one (65 mmol) was added dropwise. The
reaction mixture was stirred for 1 h, then (13.5 g, 75
mmol) of (R)-4-chloromethyl-[1,3,2]dioxathiolane
2,2-dioxide was added and the reaction mixture was
stirred overnight. The reaction was stoped by addi-
tion of 3.6 mL of H2SO4 (conc.) and water (1.3 mL).
After stirring for 1 h at room temperature, the reac-
tion mixture was neutralized by adding sat.
NaHCO3, and extracted with CHCl3 (2 x 20 mL).
The organic layers were collected, dried over anh.
Na2SO4 and evaporated. The obtained oil was puri-
fied by column chromatography using a mixture of
acetone and chloroform (1:1, v/v).
(2R)-1-(3-chloro-2-hydroxypropyl)-3-phenylpyrro-
lidin-2-one (9 a)
Yield 10.3 g (63%), Rf (acetone : CHCl3 1:1,
v/v) 0.64. 1H-NMR (CDCl3, δ ppm): 2.17 ñ 2.29 (m,
2H, CH2CH), 3.23 ñ 3.51 (m, 8H, CH2N, CHCO,
OH, NCH2CH, CH2Cl), 4.05 ñ 4.25 (m, 1H,
CHOH), 6.84 ñ 7.03 (m, 5H, arom.). 13C-NMR
(CDCl3, δ ppm): 30.5 (CH2CHCO), 46.6 (CH2N),
48.0 (CHCO), 48.9 (CH2Cl), 54.1 (CH2CHOH),
73.9 (CHOH), 126.0, 128.1, 128.8, 139.2 (arom.),
172.3 (carbonyl). Analysis: calc. for C13H16NO2Cl,
Mr = 253.72: C 61.54, H 6.36, N 5.52%; found: C
61.68, H 6.58, N 5.72%. 
(2R)-1-(3-chloro-2-hydroxypropyl)-3-methyl-3-
phenylpyrrolidin-2-one (9 b)
Yield 10.8 g (62%), Rf (acetone : CHCl3 1:1,
v/v) 0.67. 1H-NMR (CDCl3, δ ppm): 1.82 (s, 3H),
2.17 ñ 2.29 (m, 2H, CH2CH), 3.38 ñ 3.51 (m, 7H,
CH2N, OH, NCH2CH, CH2Cl), 4.07 ñ 4.32 (m, 1H,
Figure 1. Structure of parent active compounds (1) and (2) and designed compounds
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CHOH), 7.89 ñ 7.06 (m, 5H, arom.). 13C-NMR
(CDCl3, δ ppm): 22.0 (CH3), 25.4 (CH2CCO), 44.1
(CH2N), 48.9 (CH2Cl), 54.4 (CH2CHOH), 55.4 (C),
73.9 (CHOH), 126.0, 128.1, 128.8, 138.9 (arom.),
183.1 (carbonyl). Analysis: calc. for C14H18NO2Cl,
M = 267.10: C 62.80, H 6.78, N 5.23%; found: C
62.98, H 6.95, N 5.56%. 
(2R)-1-(3-chloro-2-hydroxypropyl)-3-ethyl-3-
phenylpyrrolidin-2-one (9 c)
Yield 12.4 g (68%), Rf (acetone: CHCl3 1:1,
v/v) 0.68. 1H-NMR (CDCl3, δ ppm): 0.90 (t, 3H, J =
8.0 Hz, CH3), 1.86 (q, 2H, J = 8.0 Hz, CH2CH3),
2.17 ñ 2.29 (m, 2H, CH2CH), 3.38 ñ 3.51 (m, 7H,
CH2N, OH, NCH2CH, CH2Cl), 4.07 ñ 4.32 (m, 1H,
CHOH), 6.93 ñ 7.10 (m, 5H, arom). 13C-NMR
(CDCl3, δ ppm): 8.3 (CH3), 22.9 (CH2CCO), 32.8
(CH2CH3), 44.4 (CH2N), 48.9 (CH2Cl), 54.4
(CH2CHOH), 61.3 (C), 73.9 (CHOH), 126.0, 128.1,
128.8, 138.9 (arom.), 181.7 (carbonyl). Analysis:
calc. for C15H20NO2Cl, M = 281.78: C 63.94, H
7.15, N 4.97%; found: C 64.07, H 6.99, N 5.05%.
(2R)- 1-(3-chloro-2-hydroxypropyl)-3-phenyl-3-n-
propylpyrrolidin-2-one (9 d)
Yield 13.8 g (72%), Rf (acetone : CHCl3 1:1,
v/v) 0.71. 1H-NMR (CDCl3, δ ppm): 0.90 (t, 3H, J
= 8.0 Hz, CH3), 1.26 ñ 1.34 (m, 2H, CH2CH3), 1.82
(q, 2H, J = 7.1 Hz, CH2CH2), 2.13 ñ 2.26 (m, 2H,
CH2CH), 3.38 ñ 3.51 (m, 7H, CH2N, OH,
NCH2CH, CH2Cl), 4.07 ñ 4.32 (m, 1H, CHOH),
6.97 ñ 7.13 (m, 5H, arom.). 13C-NMR (CDCl3, δ
ppm): 14.0 (CH3), 16.9 (CH3CH2), 23.2
(CH2CCO), 36.9 (CH2CH2), 44.4 (CH2N), 48.9
(CH2Cl), 54.4 (CH2CHOH), 58.8 (C), 73.9
(CHOH), 126.0, 128.1, 128.8, 139.5 (arom.), 181.7
(carbonyl). Analysis: calc. for C16H22NO2Cl, M =
295.80: C 64.97, H 7.50, N 4.74%; found: C 65.17,
H 7.75, N 5.12%.
(2R)- 1-(3-chloro-2-hydroxypropyl)-3-phenyl-3-iso-
propylpyrrolidin-2-one (9 e)
Yield 13.0 g (68%), Rf (acetone : CHCl3 1:1,
v/v) 0.64. 1H-NMR (CDCl3, δ ppm): 0.91 (d, 6H, J
= 7.5 Hz, CH3), 2.13 ñ 2.26 (m, 2H, CH2CH), 2.40-
2.46 (m, 1H, CH(CH3)2, 3.38 ñ 3.51 (m, 7H,
CH2N, OH, NCH2CH, CH2Cl), 4.07 ñ 4.32 (m, 1H,
CHOH), 6.94 ñ 7.09 (m, 5H, arom.). 13C-NMR
(CDCl3, δ ppm): 17.4 (CH3), 20.4 (CH2CH2N),
40.4 ((CH3)2CH), 44.4 (CH2N), 48.9 (CH2Cl), 54.4
(CH2CHOH), 58.8 (C), 73.9 (CHOH), 126.0,
128.1, 128.8, 139.5 (arom.), 181.7 (carbonyl).
Analysis: calc. for C16H22NO2Cl, M = 295.80: C
64.97, H 7.50, N 4.74%; found: C 65.17, H 7.75, N
5.12%.
(2S)-1-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propyl]
-3-alkyl-3-phenylpyrrolidin-2-ones (10 añe) general
procedure
5 mmol of (2R)-1-(3-chloro-2-hydroxypropyl)-
3-alkyl-3-phenylpyrrolidin-2-one (9 a-e) and 0.8 g (5
mmol) of 1-phenylpiperazine were dissolved in 5 mL
of acetonitrile. Then, 5 mmol of anhydrous K2CO3
and 0.05 mmol of TBAI were added. The reaction
mixture was stirred at room temperature for 24 h.
The inorganic salt was filtered and washed with 5
mL of MeOH. The filtrate was evaporated and the oil
obtained was purified by column chromatography
using an acetone : chloroform (1:1, v/v) mixture.
(2S)-1-[2-hydroxy-3-(4-phenylpiperazin-1-yl)-
propyl]-3-phenylpyrrolidin-2-one (10 a)
Yield 1.2 g (64%), Rf (acetone: CHCl3 1:1)
0.53; 1H-NMR (CDCl3, δ ppm:) 2.09-2.21 (m, 2H,
CH2CH (pyrrol.)), 2.38 (d, 2H, J = 7.3 Hz, CH2),
2.84 (t, 4 H, J = 7.1 Hz, CH2 (piper.)), 3.34 ñ 3.48
(m, 8H, CH2 (piper.), CH2N, NCH2CHOH), 3.51 ñ
3.58 (m, 2H, CHCO, OH), 3.93 ñ 4.08 (m, 1H,
CH2CHCH2), 6.94 ñ 7.40 (10H, m, arom.). 13C-NMR
(CDCl3, δ ppm): 30.5 (CH2CHCO), 46.6 (CH2N),
48.0 (CHCO), 54.7 (CH2CH), 56.0, 56.3 (piper.),
63.5 (CH2N), 66.5 (CHOH), 114.3, 121.9, 126.0,
128.1, 128.8, 129.6, 139.2, 149.6 (arom.), 172.3
(carbonyl). Analysis: calc. for C23H29N3O2, M =
379.50: C 72.70, H 7.70, N 11.07%; found: C 73.12,
H 7.75, N 11.12%. 
(2S)- 1-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propyl]
-3-methyl-3-phenylpyrrolidin-2-one (10 b)
Yield 1.2 g (62%), Rf (acetone , v/v: CHCl3
1:1) 0.53. 1H-NMR (CDCl3, δ ppm): 1.82 (s, 3H,
CH3), 2.20 (t, 2H, J = 7.8 Hz, CH2CH), 2.63 -2.84
(m, 6H, CH2 (piper.), CHCH2N), 3.34 ñ 3.50 (m,
9H, CH2 (piper.), CH2N, NCH2CH, OH), 3.37 ñ
4.12 (m, 1H, CHOH), 6.94 ñ 7.37 (m, 10 H, arom.).
13C-NMR (CDCl3, δ ppm): 22.0 (CH3), 25.4 (CH2C),
44.1 (CH2CH2N), 55.0 (NCH2CH), 55.1 (C), 56.0,
56.3 (piper.), 63.5 (CHCH2N), 66.5 (CHOH), 114.3,
121.9, 126.0, 128.1, 128.8, 129.6, 138.9, 149.6
(arom.), 183.1 (carbonyl). Analysis: calc. for
C24H31N3O2, M = 393.52: C 73.25, H 7.94, N
10.68%; found: C 73.12, H 7.69, N 10.47. 
(2S)- 1-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propyl]
-3-ethyl-3-phenylpyrrolidin-2-one (10 c)
Yield 1.2 g (59%), Rf (acetone: CHCl3 1:1, v/v)
0.57. 1H-NMR (CDCl3, δ ppm): 0.90 (t, 3H, J = 7.1
Hz, CH3), 1.86 (q, 2H, J = 7.1 Hz, CH3CH2), 2.24 (t,
2H, J = 7.8 Hz, CH2C), 2.67 ñ 2.80 (m, 6H, CH2
(piper.), CHCH2N), 3.34 ñ 3.51 (m, 9H, CH2CH2N,
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NCH2CH, CH2 (piper. ), OH), 3.92 ñ 4.02 (m, 1H,
CH), 6.80 ñ 7.37 (m, 10H, arom.). 13C-NMR
(CDCl3, δ ppm): 8.3 (CH2), 22.9 (CH2C), 32.8 (C),
44.4 (CH2N), 55.0 (CH2CH), 56.0, 56.3 (piper.),
61.3 (C), 63.5 (CH2N), 66.5 (CHOH), 114.3, 121.9,
126.0, 128.1, 128.8, 129.6, 138.9, 149.6 (arom.),
181.5 (carbonyl). Analysis: calc. for C25H33N3O2, M
= 407.55: C 73.68, H 8.16, N 10.31%; found: C
73.57, H 8.23, N 10.51%. 
(2S)-1-[2-hydroxy-3-(4-phenylpiperazin-1-yl)
propyl]-3-phenyl-3-n-propylpyrrolidin-2-one (10 d)
Yield 1.3 g (62%), Rf (acetone : CHCl3 1:1,
v/v) 0.53. 1H-NMR (CDCl3, δ ppm): 0.90 (t, 3H, J =
7.3 Hz, CH3), 1.30 ñ 1.39 (m, 2H, CH3CH2), 1.82 (t,
2H, J = 7.4 Hz, CH2CH2), 2.13 (t, 2H, J = 7.8 Hz,
CH2C), 2.63 ñ 2.84 (m, 6H, CHCH2N, CH2 (piper.)),
3.34 ñ 3.58 (m, 9H, CH2N, NCH2CH, CH2 (piper.),
OH), 3.97 ñ 4.12 (m, 1H, CH), 6.94 ñ 7.37 (m, 10H,
arom). 13C-NMR (CDCl3, δ ppm): 14.0 (CH3), 16.9
(CH3CH2), 23.2 (CH2CH2), 36.9 (CH2C), 44.4
(CH2N), 55.0 (CH2N), 56.0, 56.3 (piper), 58.8 (C),
63.5 (CHCH2N), 66.5 (CHOH), 114.3, 121.9, 125.9,
128.1, 128.5, 129.6, 139.5, 149.6 (arom.), 181.7
(carbonyl). Analysis: calc. for C26H35N3O2, M =
421.57: C 74.07, H 8.37, N 9.97%; found: C 73.97,
H 8.30, N 9.83.
(2S)-1-[2-hydroxy-3-(4-phenylpiperazin-1-yl)pro-
pyl]-3-phenyl-3-iso-propylpyrrolidin-2-one (10 e)
Yield 1.2 g (59%), Rf (acetone : CHCl3 1:1,
v/v) 0.56. 1H-NMR (CDCl3, δ ppm): 0.91 (d, 6H, J
= 6.4 Hz, CH3), 2.23 (t, 2H, J = 7.8, CH2CH2N),
2.43 (m, 1H, CH(CH3)2), 2.72 ñ 2.84 (m, 6H, CH2
(piper.), CH2N), 3.34 ñ 2.58 (m, 9H, CH2 (piper.),
CH2CH, CH2N, OH), 4.01 ñ 4.15 (m, 1H, CHOH),
6.94 ñ 7.37 (m, 10H, arom.). 13C-NMR (CDCl3, δ
ppm): 17.4 (CH3), 20.4 (CH2CH2), 40.4 (CH(CH3)2),
44.7 (CH2N), 55.0 (NCH2CH), 56.0, 56.3 (piper.),
63.5 (CHCH2N), 66.5 (CHOH), 67.7 (C), 114.3,
121.9, 125.5, 127.8, 128.5, 129.6, 141.2, 149.6
(arom.), 181.7 (carbonyl). Analysis: calc. for
C26H35N3O2, M = 421.57: C 74.07, H 8.37, N 9.97%;
found: C 73.91, H 8.43, N 9.94%. 
(2S)-1-[2-hydroxy-3-(4-phenylpiperidin-1-yl)pro-
pyl]-3-alkyl-3-phenylpyrrolidin-2-one (11 añe) gen-
eral procedure 
5 mmol of (2R)-1-(3-chloro-2-hydroxypropyl)-
3-alkyl-3-phenylpyrrolidin-2-one (9 a-e) and 0.8g (5
mmol) 1-phenylpiperidine were dissolved in 5 mL
of acetonitrile. Then, 5 mmol anhydrous K2CO3 and
0.05 mmol TBAI were added. The reaction mixture
was stirred at room temperature for 24 h. The inor-
ganic salt was filtered and washed with 5 mL of
MeOH. The filtrate was evaporated and the oil
obtained was purified by column chromatography
using an acetone: chloroform (1:1) mixture. 
(2S)-1-(2-hydroxy-3-(4-phenylpiperidin-1-yl)pro-
pyl)-3-phenylpyrrolidin-2-one (11 a)
Yield 1.3 g (68%), Rf (acetone : CHCl3 1:1,
v/v) 0.57. 1H-NMR (CDCl3, δ ppm): 1.92 ñ 2.19 (m,
6H, CH2CH2N, CH2 (piper.)), 2.51 ñ 2.78 (m, 7H,
CH (piper.), CH2 (piper.), CH2N), 3.34 ñ 3.58 (m,
6H, CH2N, CH2CH, OH, CH), 3.97 ñ 4.10 (m, 1H,
CHOH), 7.27 ñ 7.40 (m, 10H, arom.). 13C-NMR
(CDCl3, δ ppm): 30.5 (CH2CH2N), 33.2, 42.0, 48.8
(piper.), 46.6 (CH2N), 48.0 (CH), 54.7 (CH2CHOH),
63.8 (CH2N), 66.5 (CHOH), 126.0, 128.1, 128.8,
139.2, 146.5 (arom.), 172.3 (carbonyl). Analysis:
calc. for C24H30N2O2, M = 378.51: C 76.16, H 7.99,
N 7.40%; found: C 76.23, H 8.02, N 7.52. 
(2S)-1-(2-hydroxy-3-(4-phenylpiperidin-1-yl)pro-
pyl)-3-methyl-3-phenylpyrrolidin-2-one (11 b)
Yield 1.3 g (65%), Rf (acetone : CHCl3 1:1,
v/v) 0.59. 1H-NMR (CDCl3, δ ppm): 1.82 (s, 3H,
CH3), 1.92 ñ 2.16 (m, 6H, CH2CH2N, CH2 (piper.)),
2.51 ñ 2.70 (m, 7H, CH2 (piper.), CH (piper.),
CH2N), 3.34 ñ 3.58 (m, 5H, CH2CH2N, CH2CH,
OH), 3.99 ñ 4.12 (m, 1H, OH), 7.27 ñ 7.37 (m, 10H,
arom.). 13C-NMR (CDCl3, δ ppm): 22.0 (CH3), 25.4
(CH2CH2N), 33.2, 42.0, 48.8 (piper.), 44.1
(CH2CH2N), 55.0 (CH2CHOH), 55.4 (C), 63.8
(CH2N), 66.5 (CHOH), 126.0, 128.8, 128.1, 138.9,
146.5 (arom.), 183.1 (carbonyl). Analysis: calc. for
C25H32N2O2, M = 392.53: calc. C 76.49, H 8.22, N
7.14%; found: C 76.54, H 8.20, N 7.12%; 
(2S)-3-ethyl-1-(2-hydroxy-3-(4-phenylpiperidin-1-
yl)propyl)- 3-phenylpyrrolidin-2-one (11 c)
Yield 1.4 g (70%), Rf (acetone : CHCl3 1:1,
v/v) 0.54. 1H-NMR (CDCl3, δ ppm): 0.90 (t, 3H, J =
7.1Hz, CH3), 1.86 ñ 2.13 (m, 8H, CH2 (piper.),
CH3CH2, CH2CH3), 2.51 ñ 2.78 (m, 7H,
CHCH2N,CH2 (piper.), CH (piper.)), 3.34 ñ 3.58 (m,
5H, CH2CH2, CH2CH, OH), 4.00 ñ 4.13 (m, 1H,
CHOH), 7.27 ñ 7.37 (m, 10H, arom.). 13C-NMR
(CDCl3, δ ppm): 8.3 (CH3), 22.9 (CH2CH2N), 32.8
(CH3CH2), 33.2, 42.0, 48.8 (piper.), 44.4
(CH2CH2N), 55.0 (CH2CHOH), 61.3 (C), 63.8
(CH2N), 66.5 (CHOH), 126.0, 128.1, 128.8, 138.9,
146.5 (arom.), 181.7 (carbonyl). Analysis: calc. for
C26H34N2O2, M = 406.56: C 76.81, H 8.43, N 6.89%;
found: C 76.91, H 8.46, N 6.93%. 
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Scheme 1. Synthesis of 1-[2-hydroxy-3-(4-phenylpiperidin-1-yl)propyl]pirolidin-2-one (5)
Scheme 2. Synthesis of 1-[3-(4-phenylpiperidin-1-yl)propyl]-pirolidin-2-one (7)
Scheme 3. Synthesis of (2S)-1-[3-(4-phenylpiperazin-1-yl)- or (2S)-3-[(4-phenylpiperidin-1-yl)-2-hydroxy]- propyl-3-alkyl-3-phenyl-
pyrrolidin-2-one derivatives (10 a ñ e) and (11 a ñ e)
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(2S)-1-(2-hydroxy-3-(4-phenylpiperidin-1-yl)pro-
pyl)- 3-phenyl-3-n-propyl-pyrrolidin-2-one ((2S)-11 d)
Yield 1.3 g (63%), Rf (acetone : CHCl3 1:1,
v/v) 0.52. 1H-NMR (CDCl3, δ ppm): 0.90 (t, 3H, J =
7.3 Hz, CH3), 1.28 ñ 1.39 (m, 2H, CH3CH2), 1.82 ñ
2.13 (m, 8H, CH2CH2, CH2CH2, CH2 (piper.)), 2.63
ñ 2.78 (m, 7H, CHCH2N, CH2 (piper.), CH (piper.)),
3.36 ñ 3.55 (m, 5H, CH2CH2N, CH2CH, OH), 4.02
ñ 4.15 (m, 1H, CHOH), 7.27 ñ 7.37 (m, 10H, arom.).
13C-NMR (CDCl3, δ ppm): 14.1 (CH3), 17.8
(CH3CH2), 29.1 (CH2CH2N), 35.9 (CH2CH2), 33.2,
42.0, 48.8 (piper.), 45.3 (CH2CH2N), 55.1
(CHCHOH), 61.3 (C), 63.8 (CHOHCH2), 66.5
(CHOH), 109.7, 116.1, 126.0, 128.1, 128.8, 130.4,
135.2, 146.5, 154.2 (arom.), 176.7 (carbonyl).
Analysis:. calc. for C27H36N2O2, M = 420.59: C
77.10, H 8.63, N 6.66%; found: C 77.03, H 8.58, N
6.54%. 
(2S)-1-(2-hydroxy-3-(4-phenylpiperidin-1-yl)pro-
pyl)- 3-phenyl-3-iso-propylpyrrolidin-2-one (11 e)
Yield 1.4 g (67%), Rf (acetone : CHCl3 1:1,
v/v) 0.57. 1H-NMR (CDCl3, δ ppm): 0.90 (d, 6H, J
= 7.2 Hz, CH3), 1.92 ñ 2.13 (m, 6H, CH2CH2N, CH2
(piper.)), 2.43 ñ 2.68 (m, 8H, CH(CH3)2, CH2
(piper.), CH (piper.), CH2N), 3.34 ñ 3.58 (m, 5H,
CH2CH2N, CH2CHOH, OH), 4.03 ñ 4.16 (m, 1H,
Table 1. Affinity of 1-[3-(4-phenylpiperazin-1-yl)- or 3-(4-
phenylpiperidin-1-yl)-2-hydroxypropyl]-3-alkyl-3-phenyl-pyrro-
lidin-2-one derivatives ((S)-1, (R)-1, 5, 7, 10 a, 10 c, 10 d, 10 e,
11 a, 11 b, 11 d) and model compounds (1 and 2) towards α1-ARs
subtypes in rat cerebral cortex.
Compound pKi α1
1 (42) 5.72 
(S)-1 6.27  
(R)-1 5.58 
2 (22) 6.25  
5 5.82  
7 5.95  
10 a 5.83  
10 c 5.79  
10 d 6.43  
10 e 6.23  
11 a 6.36  
11 b 5.85  
11 d 6.05  
The means pKi values were obtained from three experiments.
Inhibition constants (Ki) were calculated according to the equation
of Cheng and Prusoff (35)
Table 2. The prophylactic anarrhytmic activity of 1-[3-(4-
phenylpiperazin-1-yl)- or 3-(4-phenylpiperidin-1-yl)-2-hydrox-
ypropyl]-3-alkyl-3-phenyl-pyrrolidin-2-one ((S)-1, 5, 7, 10 c-e, 11
a and 11 d) and model compounds 1 and 2 in adrenaline-induced
arrhythmia in anesthetized rats after i.v. administration
Compound ED50 (mg/kg)  
1 (42) 7.9
(S)-1 5.1 (4.2 ñ 6.1)  
2 2.8 (2.1 ñ 3.6)  
5 4.9 (3.7-6.4)  
7 7.6 (5.4 ñ 10.6)  
10 c 12.9 (10.7 -15.5)  
10 d 9.9 (6.7- 14.8)  
10 e 10.4 (8.0 ñ 13.5)  
11a 6.2 (4.7 ñ 8.0)  
11d 13.2 (10.6 ñ 16.5)  
tolazoline 3.4 (2.6 ñ 4.4)  
Each value was obtained from three experimental groups. Each
group consisted of six animals. The ED50 values and their confi-
dence limits were calculated according to the method of Litchfield
and Wilcoxon (39)
Figure 2. Graphical representation of the observed α1-ARs activi-
ty values versus the values predicted by the model [24] for com-
pounds 1, 2, 5 and 7
CHOH), 7.30 ñ 7.37 (m, 10H, arom.). 13C-NMR
(CDCl3, δ ppm): 17.4 (CH3), 20.4 (CH2CH2N), 40.4
(CH(CH3)2), 44.7 (CH2CH2N), 33.2, 42.0, 48.8
(piper.), 55.0 (CH2CHOH), 63.8 (CH2N), 66.5
(CHOH), 67.7 (CH2CHCO), 125.5, 126.0, 127.8,
128.1, 128.5, 128.8, 141.2, 146.5 (arom.), 181.7
(carbonyl). Analysis: calc. for C27H36N2O2, M =
420.59: C 77.10, H 8.63, N 6.66%; found: C 77.17,
H 8.76, N 6.76%. 




[3H] clonidine (Amersham), epinephrine
(Adrenalinum hydrochloricum, Polfa), norepineph-
rine (Levonor, Polfa), methoxamine (Sigma,
Aldrich Chemie GmbH), [3H] prazosin (Amersham),
tyramine (Sigma, Aldrich Chemie GmbH), sodium
heparin (Polfa), thiopental sodium (Biochemie
GmbH, Vienna)
Animals
The experiments were carried out on male
Wistar rats (180 ñ 250 g). Animals were housed in
constant temperature facilities exposed to 12/12 h
light-dark cycle and maintained on a standard pellet
diet and tap water was given ad libitum. Control and
experimental groups consisted of 8 ñ 10 animals
each. All procedures were done according to the
Animal Care and Use Committee Guidelines and
approved by the Ethical Committee of the
Jagiellonian University, KrakÛw, Poland.
Table 3. The hypotensive activity of 1-[3-(4-phenylpiperazin-1-yl)- or 3-(4-phenylpiperidin-1-yl)-2-hydroxy]-propyl-3-alkyl-3-phenyl-
pyrrolidin-2-one derivatives ((S)-1, 5, 7, 10 c, 10 d, 11 a and 11 d) in anesthetized normotensive rats after i.v. administration
Comp. Dose Pressure Control 5 min 10 min 20 min 30 min 40 min 50 min 60 min 
systolic 138.0 115.0 115.0 129.0 128.0 126.0 126.0 129.5
(S)-1 5 ± 2.6 ± 3.6*** ± 6.9** ± 2.9* ± 3.9* ± 3.3* ± 5.2* ± 9  
diastolic 120.0 104.0 109.5 109.0 112.5 118.0 119.0 116.0
± 4.7 ± 4.5*** ± 3.2 ** ± 2.9** ± 5 * ±4.5 ±6.5 ±6.9  
systolic 121.8 108.2 108.7 104.8 104.0 98.2 95.7 97.0
5 5 ± 3.0 ± 4.3 ± 5.3 ± 4.2* ± 4.7* ± 6.4*** ± 7.2***  ± 6.6***
diastolic 101.0 90.0 89.5 85.5 85.7 80.8 78.5 80.2
± 2.7 ± 5.1  ± 6.3 ± 4.5 ± 5.3  ±7.9*  ± 8.4** ± 8.2*
systolic 111.5 103.2 101.5 101.5 100.0 101.2 100.5 100.0
2.5 ± 2.5  ± 3.0  ± 2.1*  ± 1.4* ± 2.3**  ± 2.2*  ± 3.4* ± 3.5**  
diastolic 92.0 82.2 83.7 83.2 82.0 81.7 81.5 81.0
± 4.2 ± 6.1  ± 2.7 ± 4.0 ± 4.2  ± 4.2  ± 4.8  ± 4.6  
systolic 136.2 124.0 122.5 118.5 114.5 111.7 112.7 112.5
7 5 ± 5.5  ± 7.7  ± 6.7 ± 5.8*  ± 4.6**  ± 4.3***  ± 3.2***  ± 3.4***
diastolic 117.7 105.2 104.2 100.7 95.7 93.7 93.5 92.2
± 5.1  ± 6.2  ± 6.8 ± 6.4 ± 5.6* ± 5.4** ±4.9**  ± 4.0***
systolic 129.0 114.2 113.5 114.2 113.0 110.0 111.2 111.2
2.5 ± 4.6 ± 4.4*  ± 3.9* ± 4.2* ± 5.4*  ± 5.0***  ±6.9**  ± 6.6**
diastolic 107.6 93.7 93.7 95.2 94.5 93.0 94.0 94.5
± 6.4 ± 7.2  ± 7.4 ± 5.9 ± 6.6  ± 7.3  ± 8.8  ± 7.7
systolic 140.9 133.9 138. 0 135.8 139.5 137.2 140 139.5
10c 5 ± 4.9 ± 2.2* ± 3.3 ± 6.3 ± 8 ± 8.2  ± 9 ± 5
diastolic 129.2 127.3 125 129 126 129 129 128
± 6.0 3 ± 6.2 ± 8.4 ± 4.9 ± 2.9 ± 2.5 ± 4.8 ± 9.4
systolic 145.3 121 129.3 124 129 132 133 132.9
10d 5 ± 4.2 ± 4.1**** ± 3.8*** ± 5.5*** ± 7** ± 10.3* ± 8.9* ± 4.3*  
diastolic 129.5 111.0 118.0 114.3 119.0 122.0 125.0 125.0
± 6.2 ± 3.9****  ± 6.1* ± 9.4* ± 7.1* ± 5.5 ± 4.8 ± 7
systolic 148.0 119.0 119.3 125.0 131.0 138.0 135.0 139.9
11a 5 ± 9.2 ± 8.1** ± 4.9** ± 9.5* ± 7.1* ± 10 ± 3.9* ± 9
diastolic 124 115 112.7 117.0 119.0 117.0 117.9 118.0
± 5.9 ± 1.4*  ± 3.0* ± 8.0 ± 6.6 ± 9.2 ± 10.0 ± 7.0
systolic 141.3 130.9 135 135.8 137.5 137.9 138 139.0
11d 5 ± 4.9 ± 3.0** ± 1.3* ± 3.3* ± 4.0 ± 7.2 ± 7.0 ± 5.9
diastolic 126 119 119.7 120.2 119 119.7 122.8 123
± 9.3 ± 1.1* ± 4.2 ± 7.0 ± 9.4 ± 9.0 ± 6.4 ± 7.9
The data are the means of six experiments ± SEM. Statistical analyses were performed using a one-way ANOVA: * p < 0.05; ** p < 0.02;
*** p < 0.01; **** p < 0.001
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Figure 3. The effect of compound 5 on blood pressure response to epinephrine, norepinephrine and methoxamine
Figure 4. The effect of compound 7 on blood pressure response to epinephrine, norepinephrine and methoxamine
Reference compounds
Compound 1 was used as a reference.
Statistical analysis
The data are expressed as the mean ± SEM.
The statistical significance was calculated using a
one-way ANOVA. Differences were considered sig-
nificant when p < 0.05.
α1-Adrenoceptor radioligand binding assay
The experiment was carried out on rat cerebral
cortex. [3H]prazosin (19.5 Ci/mmol,) was used. The
brains were homogenized in 20 volumes of ice-cold
50 mM Tris-HCl buffer (pH 7.6) and were centrifuged
at 20 000 ◊ g for 20 min (0 ñ 4OC). The cell pellet was
resuspended in the Tris-HCl buffer and centrifuged
again. Radioligand binding assays were performed in
plates (MultiScreen/Millipore). The final incubation
mixture (final volume 300 mL) consisted of 240 mL
of the membrane suspension, 30 mL of [3H]prazosin
(0.2 nM) solution and 30 mL of the buffer containing
seven to eight concentrations (10-11 ñ 10-4M) of the
tested compounds. To measure the unspecific binding,
10 mM phentolamine was applied (34). The incuba-
tion was terminated by rapid filtration over glass fiber
and placed in scintillation vials with a liquid scintilla-
tion cocktail. Radioactivity was measured in a WAL-
LAC 1409 DSA liquid scintillation counter. All assays
were made in duplicate. The radioligand binding were
analyzed using an iterative curve-fitting routine
(GraphPAD/Prism, Version 4.0 ñ San Diego, CA,
USA). Ki values were calculated based on the method
described by Cheng and Prusoff (35).
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Figure 6. The effect of compound 10d on blood pressure response to epinephrine, norepinephrine and methoxamine
Figure 5. The effect of compound (S)-1 on blood pressure response to epinephrine, norepinephrine and methoxamine
Prophylactic antiarrhythmic activity in a model
of adrenaline-induced arrhythmia according to
Szekeres and Papp (36)
Arrhythmia was evoked in thiopental (60
mg/kg, i.p.) ñ anesthetized rats by i.v. injection of
adrenaline (20 mg/kg). The tested compounds were
administered intravenously 15 min before adrena-
line. The criterion of antiarrhythmic activity was the
lack of premature beats and the inhibition of rhythm
disturbances in comparison with the control group
(ventricular bradycardia, atrioventricular block,
ventricular tachycardia or ventricular fibrillation).
The cardiac rhythm disturbances were recorded for
15 min after adrenaline injection. ECGs were ana-
lyzed according to the guidelines of the Lambeth
Convention (40) on ventricular premature beats
(VBs), bigeminy, salvos (less than four successive
VBs), ventricular tachycardia (VT, four or more
successive VBs) and ventricular fibrillation (VF).
The influence on blood pressure
Male Wistar normotensive rats were anes-
thetized with thiopental (50 ñ 75 mg/kg, i.p.) The
right carotid was cannulated with polyethylene tube
filled with heparin in saline to facilitate pressure
measurement using the Datamax apparatus
(Columbus Instruments). The studied compounds
were injected in a single dose of 2.5 or 20 mg/kg
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into the caudal vein after a 5 min stabilization peri-
od at a volume equivalent to 1 mL/kg.
RESULTS
As a staring material for the synthesis of com-
pound 5 earlier described 1-(2,3-epoxypropyl)-
pyrrolidin-2-one (4), which was synthesized from
pyrrolidin-2-one (3) and 1-chloro-2,3-
epoxypropane, was used (38, 39). Its aminolysis
with 4-phenylpiperidine performed in closed vessel
in microwave reactor gave racemic mixture of 1-[2-
hydroxy-3-(4-phenylpiperidin-1-yl)propyl]-piro-
lidin-2-one (5) with 68% yield (Scheme 1).
The compound 1-[3-(4-phenylpiperidin-1-
yl)propyl]-pirolidin-2-one (7) was obtained by a
simple two stage reaction. Firstly, 1-(3-chloro-
propyl)pyrrolidin-2-one (6) was synthesized. This
compound was obtained by alkylation of pyrrolidin-
2-one (3) with 1-bromo-3-chloro-propane. The reac-
tion was carried out in tetrahydrofuran (THF) using
NaH as a base. Then, heating of compound 6 and 4-
phenylpiperidine in closed vessel in a microwave
reactor, yielded compound 7 in 73% yield. 
Taking into consideration that (S) enantiomers
of compound 1 and its analogues displayed higher
affinity for α1-ARs than the (R) ones, 1-[3-(4-
phenylpiperazin-1-yl)-2-hydroxy]propyl- or 1-[3-
Figure 7. The effect of compound 10 e on blood pressure response to epinephrine, norepinephrine and methoxamine
Figure 8. The effect of compound 11 a on blood pressure response to epinephrine, norepinephrine and methoxamine
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(4-phenylpiperidin-1-yl)-2-hydroxy]propyl- com-
pounds having 3-alkyl-3-phenylpyrrolidin-2-one
fragment were obtained only as derivatives having
(S) configuration on asymmetric carbon atom of the
propyl chain. For this reactions, an earlier elaborat-
ed method was applied (23). As a starting material
for this synthesis, (R)-4-chloromethyl-[1,3,2]dioxathio-
lane 2,2-dioxide was used (37, 38). This compound
with relevant substituted pyrrolidin-2-one (8añe)
gave (2R)-2-hydroxy compounds 9añe, with yields
varied between 62 and 72%. Finally, the alcohols
9añe with relevant 4-phenylpiperazine or 4-
phenylpiperidine, in the reaction of phase transfer
catalysis catalyzed by tetrabutylammonium iodide
(TBAI) and carried out in a mixture of acetoni-
trile/K2CO3, gave (2S) enantiomers of 1-[3-(4-
phenylpiperazin-1-yl)-2-hydroxypropyl]-3-aryl-3-
phenylpyrrolidyn-2-one (10añe) and 1-[3-(4-
phenylpiperidin-1-yl)-2-hydroxypropyl]-3-aryl-3-
phenylpyrrolidyn-2-ones (11añe) with 59-70% yield
(Scheme 3). 
The structures of the new compounds were
confirmed by elemental analysis and spectral data. 
In the present study, several pharmacological tests
were carried out to assess α1-AR affinity, antiar-
rhythmic and hypotensive activity of the novel
pyrrolidin-2-ones derivatives (S)-1, (R)-1, 5, 7, 10a-
e and 11a-e.
The pharmacological profile of the new com-
pounds was evaluated by radioligand binding assays
(the ability to displace [3H] prazosin from α1-ARs)
on rat cerebral cortex (34, 35). All tested compounds
displaced [3H]prazosin from cortical binding sites
(pKi α1-ARs 5.82 - 6.43). The results obtained are
presented in Table 1. 
The prophylactic antiarrhythmic activity of
compounds (S)-1, (R)-1, 5, 7, 10a-e and 11a-e was
determined using a model of adrenaline-induced
arrhythmia in rats (37). Intravenous (iv) injections of
adrenaline at a dose of 20 mg/kg caused reflex
bradycardia (100%), supraventricular and ventricu-
lar extrasystoles (100%), bigeminy and ventricular
tachycardia (50%) in rats, which led to the death of
ca. 50% of animals within 10 ± 5 min. Compounds
(S)-1, 5, 7, 10c-e, 11a and 11d injected intravenous-
ly 15 min before adrenaline, diminished the occur-
rence of extrasystoles and reduced mortality. The
ED50 values are presented in Table 2. These data
show that compound (S)-1 was the most active, its
ED50 value is 4.9 mg/kg.
The hypotensive activity of compounds (S)-1,
(R)-1, 5, 7, 10a-e and 11a-e was determined after iv
administration to normotensive anesthetized rats at
doses of 2.5 and 5.0 mg/kg. The results are present-
ed in Table 3. Compounds (S)-1, 5, 7, 10 c, 10d, 11a
and 11d significantly decreased systolic and dias-
tolic pressure. This effect persisted for more than 60
min.
To examine the mechanism of the hypotensive
effects of these compounds, their influence on the
pressor responses to epinephrine, norepinephrine,
methoxamine and tyramine were studied. These
compounds given iv to rats caused a pressor
response at the following doses: epinephrine 2
mg/kg, norepinephrine 2 mg/kg, methoxamine 150
mg/kg, tyramine 200 mg/kg. Compounds 10d and
10e given iv in doses of 2.5 mg/kg antagonized the
pressor response elicited by epinephrine, norepi-
nephrine and methoxamine. Compounds (S)-1, 5, 7
and 11a given in a dose of 2.5 mg/kg decreased pres-
sor response provoked by epinephrine and methox-
amine. (Fig. 3 -8) All of these effects were statisti-
cally significant. However, compounds (R)-1, 10a,
10b, 10c, 11b, 11c, 11d and 11e) had no statistically
significant influence on the systolic pressor response
generated by epinephrine, norepinephrine, methox-
amine and tyramine (data not shown).
RESULTS AND DISCUSSION
All the newly synthesized compounds (S)-1,
(R)-1, 5, 7, 10a, 10c, 10d, 10e, 11a, 11b, 11d were
found to possess an affinity toward α1-ARs, which
was comparable to the affinity of the earlier report-
ed compounds. The highest affinity for α1-ARs (pKi
6.43) was displayed by compound 10d, which is a
phenylpiperazine derivative with phenyl and n-
propyl group in the 3rd position of the pirrolidin-2-
one ring. Among the isomers of compounds 1 high-
er affinity for α1-ARs was displayed by enantiomer
(S). The replacement of piperazine ring by piperi-
dine one gave compounds 5 and 7, which affinity to
α1-ARs were comparable to parent compounds 1
and 5. In case of phenylpiperazine derivatives 1 and
10a-e, the introduction of phenyl- 10a, or phenyl-
and ethyl-, n-propyl- or iso-propyl- 10c-e into 3rd
position of pyrrolidin-2-one moiety resulted in the
compound having higher than parental compounds
affinity for α1-AR. The increase of α1-ARs affinity
was also observed for compounds having piperidine
ring and phenyl- or phenyl and methyl- or n-propyl-
substituent in the 3rd position of pyrrolidin-2-one
moiety. 
In order to better understand the mechanism of
action displayed by tested compounds, their influ-
ence on the pressor response to epinephrine, norepi-
nephrine, methoxamine and tyramine was tested. It
is generally accepted that α1-ARs antagonists invert
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pressor response to epinephrine, only partially invert
that of norepinephrine, diminish the pressor
response of methoxamine and tyramine, and poten-
tiate the hypertensive effect of norepinephrine. The
results of these studies are in good agreement with
radioligand binding investigations and confirm the
α-ARs antagonist activity of the compounds
obtained. The compounds obtained diminished or
prevented the appearance of epinephrine-induced
arrhythmia symptoms. The ED50 value obtained for
compound 5 was 4.9 mg/kg, comparable to that dis-
played by tolazoline (the commonly used reference
compound in adrenaline-induced model of arrhyth-
mia) and that displayed by compound 1. 
The pyrrolidin-2-one derivatives obtained: (S)-
1, (R)-1, 5, 7, 10a-e and 11a-e, were also tested for
their hypotensive activity in normotensive anes-
thetized rats. Compounds: (S)-1, 5, 7, 10c, 10d, 11a
and 11d significantly decreased the systolic and
diastolic pressure. The highest hypotensive activity
was displayed by compounds 5 and 7. 
To probe the true predictive power of given
QSAR model (24), the comparison of the predictive
and observed activities of compounds that were not
used in the model development was performed (41). 
In this study, the following methodology have
been applied. First, four most potent compounds
were chosen from early tested derivatives. For these
new derivatives the statistical tests showed the cor-
relation coefficient Q2 of 0.93, which proves a good
predictability of earlier proposed model. This is also
shown on the plot (Fig. 2.) of the observed α1-
adrenoreceptor binding affinity vs. predicted by the
model. 
In the next step, ten analogues of parent com-
pounds were grouped in two subsets: arylpiperazinyl
analogues (compounds 10añe) and arylpiperidinyl
analogues (compounds 11añe). Then, the statistical
external test of proposed model in both group of com-
pounds 10 and 11 was performed. In order to identify
the effect of the molecular structure on the α1-ARs
activity for two newly selected groups, all calcula-
tions were conducted according to the same calculat-
ing protocol as it was described in (24). The obtained
correlation coefficients were found to be Q211  0.30
and Q210  0.50, respectively. These results suggest
that for the α1-adrenoreceptor affinity, the most
important structural feature is the presence of
arylpiperazinyl moiety in the molecular skeleton. 
CONCLUSION
The synthesis and preliminary pharmacologi-
cal data for several new 1-[3-(4-arylpiperazin-1-
yl)propyl]-3-alkyl-3-phenylpyrrolidin-2-one and 1-
[3-(4-arylpiperidin-1-yl)propyl]-3-alkyl-3-phenyl-
pyrrolidin-2-one derivatives were described. Some
of the compounds obtained were found to possess an
affinity for α1-AR comparable to that of the refer-
ence compounds 1 and 2. In case of compound 1, the
absolute configuration of asymmetric carbon atom is
important for its antiarrhythmic and hypotensive
activities. The introduction of the phenyl- and iso-
propyl- groups into pyrrolidin-2-one fragment
resulted in compounds which in in vitro studies dis-
played antiarrhytmic and hypotensive activity. The
replacement of the piperazine ring by a piperidine
one led to compounds which have an affinity com-
parable to their parent compound for both α1-ARs.
The pharmacological results and binding studies
suggested that the antiarrhythmic and/or hypoten-
sive effects of these compounds were related to their
adrenolytic properties. More extensive structure
activity relationship studies are in progress and will
be reported in due course. The obtained results are
also in good agreement with the earlier descried
QSAR model.
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